CVBT Discusses Advances in Drug Development Program for New Stroke Treatments.

LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT.OB) announced today that its Chief Operating and Scientific Officer, Jack Jacobs, Ph.D., presented the company's recent progress in its efforts to bring new therapeutics to the market for the treatment of stroke. His lecture was delivered on February 22, 2006 at the International Regenerative Medicine Foundation's 3rd annual conference entitled "New Science for a Better Medicine."

The lecture reviewed the promising data the company has collected to date to reduce the size of experimental strokes in animals. CVBT is developing human FGF-1, a protein which is a potent neuroprotective agent, as well as a stimulator of enhanced blood perfusion in the brain. In animals receiving an experimental stroke, the FGF-1 protein decreased the area of the stroke, resulting in a significant decrease in neurological deficits in these animals. The FGF-1 was administered to the animals up to 8 hours after the stroke was given, and a reduction in the stroke area and the number of neurological deficits was still observed, which, if it can be shown in humans, has potential clinical significance.

Dr. Jacobs also reviewed progress in a new initiative CVBT has launched in the area of stroke recovery. As human FGF-1 is a potent stimulator of new nerve growth, it has the potential to repopulate damaged areas of the brain with new neurons. Preclinical experiments with FGF-1 in animals with a chronic stroke condition indicated a significant increase in neuronal density in the areas affected by the stroke.

Daniel Montano, Chief Executive Officer of CVBT, commented, "Over 700,000 Americans will suffer a stroke this year and almost 5 million patients are currently suffering the often devastating consequences from a previous stroke. The financial and emotional burden for these patients is overwhelming and there exists no widely accepted therapy for these individuals. We are very excited over the preclinical results with our protein growth factor, human FGF-1. Not only is this biological product showing excellent efficacy in acute strokes, but the protein is also showing promise as a possible stroke recovery agent. We are committed to moving this protein forward into the clinic to see if our success in animals can be translated to stroke patients, who have very few therapeutic choices."

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding our future revenues, cash usage and our cash flow breakeven point are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of Cardio Vascu-Grow(TM), market acceptance of CardioVascular BioTherapeutics, Inc. products by our customers, future revenues, future expenses, future margins, cash usage, and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.